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ABSTRACT OF THESIS

THE EFFECTS OF CURCUMIN AND FENUGREEK SOLUBLE FIBER ON THE
PHYSICAL WORKING CAPACITY AT THE FATIGUE THRESHOLD, PEAK
OXYGEN CONSUMPTION, AND TIME TO EXHAUSTION

Curcumin, a polyphenol, has been suggested to improve metabolic byproduct
clearance and increase nitric oxide production in working muscle. These purported
effects may delay neuromuscular fatigue. Therefore, the purpose of this study was to
examine the effects of curcumin in combination with fenugreek (CUR) or fenugreek
soluble fiber alone (FEN) on the neuromuscular fatigue threshold (PWC ), time to
FT

exhaustion (Tlim) on a graded exercise test (GXT), and 𝑉̇ O2 peak in untrained subjects.
Forty-seven, college-aged, aerobically untrained individuals were randomly assigned to
one of three supplementation groups; placebo (PLA, n=15), curcumin + fenugreek,
CurQfen® (CUR, n=18), or fenugreek soluble fiber (FEN, n=14). All subjects performed
a maximal GXT on a cycle ergometer to determine the PWCFT , Tlim, and V̇O2 peak before
(PRE-test) and after (POST-test) 28 days of daily supplementation. Statistical analyses
included 3 separate, one-way ANCOVAs to determine if there were any differences
among the groups (PLA, CUR, FEN) for adjusted post-test scores for the PWCFT ,
V̇O2 peak, and Tlim. The respective pre-test score was used as the covariate. In addition,
reliability analyses (PRE- to POST-test) for the PLA group were used to calculate the
minimal difference needed to be real (MD). The adjusted POST PWC FT values showed
no statistical differences between groups (F= 3.141p= 0.053); however pairwise LSD

comparisons indicated a significant difference between the CUR and PLA groups (p=
0.016), but not between the CUR and FEN groups. Therefore, separate one-way
ANCOVAs were used to examine the adjusted PWC FT means for the PLA vs. CUR (F =
4.906, p =0.035) and the PLA vs. FEN (F = 2.969, p = 0.097). The one- way ANCOVA
for 𝑉̇ O2 peak (F= 0.612 p= 0.547) and Tlim (F = 0.688, p = 0.508) values showed no
statistical difference among the groups. Individual responses in each group showed ~
20% of subjects in the CUR group, ~ 7% in the FEN group, and ~6% in the PLA group
had values greater than the MD for the PWCFT , but none of the subjects in the PLA, FEN,
or CUR groups exceeded the MD for 𝑉̇ O2 peak or Tlim. These findings indicated
CurQfen® supplementation increased the PWCFT compared to a placebo, but not
compared to fenugreek soluble fiber alone. However, there were no effects of CurQfen®
on V̇O 2 peak or Tlim. The mechanisms responsible for delaying time to neuromuscular
fatigue may include increased NO production and increased blood flow to remove
metabolic byproducts; however, the cellular changes which could lead to increases in Tlim
and 𝑉̇ O2 peak may not have been sensitive to the GXT protocol or the given dosage of
curcumin supplementation. Considering individual responses, CurQfen®
supplementation resulted in a real change in the PWC FT for a small portion of the subjects
(~20%). These findings suggested that CurQfen® supplementation without exercise
training may help to improve time to neuromuscular fatigue in certain individuals, but the
group mean analyses were not necessarily reflective of the responses for a majority of the
subjects.
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CHAPTER 1. INTRODUCTION
Curcumin is an active ingredient of polyphenolic curcuminoids, which are found
in the spice turmeric (Boonla et al. 2014). Curcumin has been well studied in clinical
investigations over the last few decades and has been shown to have anti-inflammatory,
anti-cancer, anti-diabetic, anti-hypertensive, anti-dementia and antioxidant properties
(Boonla et al. 2014). Many of the purported effects of curcumin are related to reducing
oxidative stress as well as improving markers of vascular function and cardiac
performance in animal models (Boonla et al. 2014). Recent studies, however, have also
demonstrated that curcumin supplementation may increase blood antioxidant capacity
and reduce exercise-induced oxidative stress in humans (Takahashi et al. 2013).
Specifically, curcumin supplementation has been shown to offset muscle damage and
functional deficits associated with the eccentric nature of downhill running (Davis et al.
2007). Previous investigators have reported decreased markers of muscle damage,
including inflammatory cytokines and creatine kinase after curcumin supplementation
compared with a placebo (Davis et al. 2007). These decreases in inflammatory markers
may have offset some of the performance deficits associated with eccentric exerciseinduced muscle damage (Davis et al. 2007).
Recently, curcumin has been shown to decease the accumulation of metabolic
byproducts such as lactate and ammonia (Sahin et al. 2016) during acute exercise bouts.
Specifically, it was reported (Sahin et al. 2016) that decreased levels of lactate and
muscle malondialdehyde were associated with increased run times to exhaustion in
rodents supplemented with curcumin compared to a placebo. It was suggested that the
1

increased clearance of metabolic byproducts with curcumin supplementation might
potentially be linked to increased production of nitric oxide (NO), a potent vasodilator,
and the subsequent vasodilatory response (Boonla et al 2014). Thus, previous research
(Boonla et al. 2014, Sahin et al. 2016, Takahashi et al. 2013) has shown the potential for
curcumin to have a wide spectrum of bioactivities that may promote health as well as
improve endurance performance. There are currently limited data, however, regarding the
effects of curcumin supplementation on submaximal and maximal exercise performance
in humans (Boonla et al. 2014).
The physical working capacity at the fatigue threshold (PWC FT ) is an
electromyographic (EMG) technique that theoretically estimates the highest power output
that can be maintained for an extended period of time without evidence of neuromuscular
fatigue (deVries et al 1987, 1990). Speciﬁcally, during a continuous incremental test, the
PWCFT is defined as the average of the highest power output that results in no signiﬁcant
change in EMG amplitude (a nonsignificant slope coefficient) and the lowest power
output that results in a signiﬁcant increase in EMG amplitude (a significant positive slope
coefficient) (deVries et al 1987, 1990). An important contributing factor to the etiology
of neuromuscular fatigue is the accumulation of various metabolic byproducts and/or ions
(i.e., inorganic phosphate, hydrogen ions, ammonia and potassium) (Camic et al 2010,
Zuniga et al 2010, Bergstrom et al 2013) that interfere with skeletal muscle contractile
mechanism and propagation of the action potential along the sarcolemma (Clausen 2013,
Enoka and Stuart 1992, Gladden 2004, MacLaren et al 1989, Robergs et al 2004,
Westerblad et al 2002). Previously, investigators (Camic et al. 2010) examined the effects
of daily oral administration of arginine-based supplements for 4 weeks on the PWCFT in
2

aerobically untrained men. Like curcumin, one of the physiological actions of arginine is
to up regulate nitric oxide (NO) production and increase endothelium-dependent
vasodilation (Boonla 2014). The authors (Camic et al. 2010) reported significant
increases in the PWCFT after supplementation with arginine compared to a placebo. Thus,
it is possible that curcumin supplementation may work similarly to arginine to delay the
onset of neuromuscular fatigue and the PWC FT through NO-mediated vasodilation
(Boonla et al. 2014) and improved metabolic byproduct clearance (Sahin et al 2016).
Previous investigators (Sahin et al. 2016) have reported increased run times to
exhaustion in rodents supplemented with curcumin compared to a placebo. Consistent
with the findings by Sahin et al. (2016), Huang et al. (2015) reported that curcumin
supplementation dose-dependently increased grip strength and endurance performance
compared to the vehicle treatment (Huang et al 2015). Furthermore, previous
investigators have shown that curcumin supplementation, in combination with endurance
training, has the potential to accelerate mitochondrial biogenesis in skeletal muscle by
increasing cAMP levels (Hamidie et al 2015). Peripheral cellular changes, such as
increased mitochondrial density, have been shown to improve submaximal performance,
(Basset 2000). Thus, it is possible the cellular effects of curcumin to improve markers of
aerobic respiration may also delay time to fatigue and improve maximal oxygen
consumption (V̇O2 ) during incremental exercise.
Curcumin has poor absorption into the intestines and consequently low
bioavailability in the blood, and thus has been combined with other compounds to
improve absorption and increased blood concentration levels (Krishnakumar et al 2012).
One ingredient that has been studied in combination with curcumin is the naturally
3

growing plant, fenugreek soluble fiber (Krishnakumar et al 2012). The galactomannan
component of fenugreek has been combined with curcumin (CurQfen®) to increase
absorption from the small intestine (Krishnakumar et al 2012). Galactomannan is a
soluble fiber guar gum, and a potential active component of fenugreek seeds
(Srichamroen et al 2008). Specifically, galactomannans from fenugreek have been shown
to have increased effects on glycemic and lipidemic status in rats (Srichamroen et al
2008). Thus, it is possible the fenugreek component in CurQfen® may increase FFA
release and decrease insulin levels, supporting improvements in submaximal exercise
performance markers. No previous studies, however, have examined the effects of
supplementation with curcumin in combination with fenugreek soluble fiber or fenugreek
soluble fiber alone on submaximal or maximal indices of endurance performance.
Therefore, the purpose of this study was to examine the effects of curcumin in
combination with fenugreek (CUR) or fenugreek soluble fiber alone (FEN) on the
neuromuscular fatigue threshold (PWC ), time to exhaustion (Tlim ) on a graded exercise
FT

test (GXT), and 𝑉̇ O2 peak in untrained subjects. Based on the results of previous studies
(Boonla et al. 2014, Sahin et al. 2016, Takahashi et al. 2013), it was hypothesized that
curcumin supplementation would delay the onset of neuromuscular fatigue and increase
the PWCFT as well as increase Tlim and 𝑉̇ O2 peak compared to a placebo.

4

CHAPTER 2. REVIEW OF LITERATURE
2.1

Curcumin: Mechanisms of Action

Boonla et al. (2014)
Previous studies have shown that increased production of oxidants, reduced nitric
oxide (NO) bioavailability, and reduced activity of antioxidants in the vascular system
are involved in hypertension and cardiovascular disease. Research has found that
polyphenols play an important role in the maintenance of health and prevention of
diseases. Curcumin is an active ingredient of polyphenolic curcuminoids extracted from
the rhizomes of the spice turmeric. Curcumin is well known for its anti-inflammatory,
anti-cancer, anti-diabetic, anti-hypertensive, anti-dementia and antioxidant properties and
recent studies have shown that curcumin reduces oxidative stress in rodent models.
However, there have been no reports about the activity of curcumin in 2kidney-1clip (2K1C)-induced hypertension-induced endothelial dysfunction and vascular remodeling.
Therefore, the present study was designed to investigate the effects of curcumin on 2K1C - induced hypertension, endothelial dysfunction, vascular remodeling and oxidative
stress in male rats. The experimenters randomly placed the rats into the sham operated
groups or 2K-1C groups. Hypertension was induced by clipping the left renal artery with
a silver clip in groups 3-5. Group 1 rats were sham operated and received the control,
propylene glycol, and group 2 sham operated rats received 100 mg/kg/day of curcumin.
Groups 3–5 were clipped rats that received propylene glycol alone, 50 mg/kg/day of
curcumin and 100 mg/kg/day, respectively. After 6 weeks of treatment, the authors found
that curcumin ameliorated hemodynamic performance in 2K-1C hypertensive rats, by
reducing blood pressure, increasing hindlimb blood flow and decreasing hindlimb
5

vascular resistance. The results also showed that curcumin attenuated hypertensioninduced oxidative stress and vascular structural modifications. Overall, the authors
concluded that the mechanisms responsible for the antihypertensive action of curcumin in
2K-1C hypertension- induced endothelial dysfunction and vascular remodeling involve
the improvement of nitric oxide bioavailability and a reduction in oxidative stress.
Sahin et al. (2016)
The purpose of this study was to investigate the effects of curcumin
supplementation on oxidative stress markers, exercise endurance, performance, and
changes in serum and muscle proteins in rats following a test to exhaustion. This study
used 28 male rats, assigned to one of four different treatment groups 1) control, 2) no
exercise + curcumin supplement, 3) exercise only 4) exercise + curcumin
supplementation. Supplementation was administered every day for 6 weeks in the form of
100 mg·kg CurcuWin oral tablets. The rodents completed a 6-week exercise period in
-1

which they exercised on a motor driven rodent treadmill 5 days a week for 45 minutes at
a rate of 25 m·min . Following the 6-week exercise protocol, the rats were sacrificed and
-1

blood and muscle samples were analyzed for muscle markers, oxidative stress, and
antioxidant markers. The results showed there were decreased levels of lactate and
muscle malondialdehyde in the treatment groups which received the curcumin
supplement. The run time to exhaustion also improved in the supplement groups and
muscle nuclear factor and heat shock protein levels were significantly lower in group 4
(exercise + curcumin). The results of this study suggested that curcumin may have the
ability to help prevent muscle damage during exercise by regulating certain proteins,
which can lead to increased endurance and exercise performance.
6

Takahashi et al. (2013)
The purpose of this study was to investigate the effects of curcumin
supplementation on exercise-induced oxidative stress (reactive oxygen species [ROS]) in
humans. Ten untrained male subjects (23-30 years of age) were included in this study.
Prior to supplementation, the subjects performed a baseline test to determine the VO

2

max. Each subject then participated in 3 laboratory- based trials in a randomized order:
(1) placebo (control), (2) single curcumin supplementation (90 mg only before exercise)
and (3) double curcumin supplementation (90 mg before and immediately after exercise).
A washout period of at least one week was included between each condition trial. For
each trial, the subjects exercised at 65% of their VO

2max

for 60 minutes. Blood samples

were taken pre-exercise, immediately after, and 2 hours post exercise. The results showed
that the curcumin supplementation trials had decreased exercise-induced serum
concentrations of d-ROMs and TRX-1 and increased serum BAP concentrations and
plasma GSH after exercise. There were no changes in heart rate or RPE among the three
trials. These findings suggested that curcumin supplementation may increase blood
antioxidant capacity, and, therefore help to decrease exercise-induced oxidative stress.
Summary
Curcumin, an active ingredient of polyphenolic curcuminoids extracted from the
rhizomes of the spice turmeric is well known for its an anti-inflammatory, anti-cancer,
anti-diabetic, anti-hypertensive, anti-dementia and antioxidant properties (Boonla et al
2014). Recently, curcumin has also been shown to decrease hypertension- induced
oxidative stress and vascular structural modifications (Boonla et al. 2014). Curcumin has
also shown to reduce blood pressure, increase hindlimb blood flow, and decreasing
7

hindlimb vascular resistance in mice. In addition, curcumin supplementation has been
shown to improve NO bioavailability and reduce oxidative stress (Boonla et al. 2014), A
study by Takahashi et al. (2013) showed that curcumin also has physiological effects on
human subjects as well, including decreased exercise-induced oxidative stress. These
findings extended those of the rodent study by Boonla et al. (2014) and suggested
curcumin may have the potential to improve endurance performance in humans
(Takahashi et al. 2013).

2.2

Physiological and Performance Effects of Curcumin supplementation

Davis et al. (2007)
The purpose of this study was to investigate the effects of curcumin
supplementation on muscle damage and functional deficits associated with downhill
running in rodents. The heavy eccentric muscle contraction in downhill running has been
linked to increased muscle fiber damage, inflammation, and delayed onset muscle
soreness (DOMs) as well as several other functional deficits. The mice used in this study
were randomly assigned to one of four groups, 1) downhill running + placebo, 2)
downhill running + curcumin, 3) uphill running + placebo, or 4) uphill running +
curcumin. The “control” in this study was the uphill running group, since it has been
shown to produce little to no muscle damage and inflammation. Previous studies have
shown that voluntary and involuntary running in rodents was significantly decreased
following a downhill run for up to 4 days. The suggested reasoning behind this decrease
in performance is due to inflammation including increases in brain IL-1 associated with
downhill running. The authors hypothesized that the anti-inflammatory activity of

8

curcumin would decrease recovery time following a downhill run and increase running
performance due to a reduction in inflammation-induced deficits in regeneration of
muscle fibers, soreness, and central nervous system fatigue. Curcumin supplementation
was administered to the mice in the form of a food pellet containing 10 mg of curcumin
powder (Down-Cur and Up-Cur), and the placebo groups were fed a food pellet without
curcumin (Down-Plac and Up-Plac)] every day for 3 days prior to the up/downhill run.
Following supplementation, the mice performed their initial uphill/downhill run tests.
Two groups of mice (Down-Plac and Down- Cur) ran on a rodent treadmill at -14% grade
and the other two groups (Up- Plac and Up- Cur) ran at a +14% grade at a rate of
22m/min for 150 minutes. Following the uphill/downhill runs, a subset of mice were used
to assess recovery of running performance. These mice ran to fatigue on a motorized
treadmill at 36 m/min and 8% grade at either 48 or 72 h post-up/downhill run. A second
subset of mice were used to assess recovery of voluntary activity following the
up/downhill run on the rodent treadmill. Voluntary wheel running activity during the
“active” dark period was measured automatically for 7 consecutive days. The results
showed that downhill running was in fact associated with an increase in inflammatory
cytokines and creatine kinase, however, the increase in these metabolic byproducts were
offset in the group that received the curcumin supplement. The groups who received the
curcumin supplement also showed increased voluntary run times as compared to those
who received the placebo and the groups who participated in the involuntary run. The
importance of these results suggest that the anti-inflammatory phytochemical curcumin
can decrease recovery time following high intensity eccentric exercise, known to produce
muscle damage and DOMS. Curcumin also appears to be capable of enhancing a
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behavioral response (spontaneous running), which implied an important central nervous
system component (e.g., drive, motivation) that may be related to less pain and reduced
inflammatory cytokines.
Huang et al. (2015)
The aim of this study was to evaluate the potential benefits of curcumin
supplementation in a mouse model on physical performance test and exhaustive
swimming. The authors hypothesized that curcumin supplementation may mediate
exercise-induced metabolites, energy distribution, and even improve physical
performance. This experiment used male mice, which were randomly placed into one of
four groups to receive treatment by oral gavage: placebo control (water), curcumin
supplement at 12.3 mL·kg ·day , 24.6 mL·kg ·day , and 61.5 mL·kg ·day . The
-1

-1

-1

-1

-1

-1

supplementation period lasted a total of 28 days. Each mouse subject was tested for its
forelimb grip strength, and completed an exhaustive swimming test to evaluate
performance and time to fatigue. The physical fatigue-associated biomarkers included,
serum lactate, ammonia, blood urea nitrogen (BUN), and glucose and tissue damage
markers such as aspartate transaminase (AST), alanine transaminase (ALT), and creatine
kinase (CK). The results of this study showed a dose-dependent response for curcumin
supplementation on increased grip strength and endurance performance and significantly
decreased lactate, ammonia, BUN, AST, ALT, and CK levels post exercise. Muscular
glycogen content, an important energy source for exercise, was also significantly
increased in the groups who received the curcumin supplement as compared to the
placebo. From these results, the authors concluded that curcumin supplementation may
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have a wide spectrum of bioactivities for promoting health, improving exercise
performance, and preventing fatigue.
Summary:
Recent studies have observed the physiological and performance effects of
curcumin supplementation, particularly in animal subjects. Davis et al. (2007) reported
increased voluntary run times for those mice receiving the curcumin supplement
compared to those who received the placebo. These results suggested that the antiinflammatory phytochemical curcumin can decrease recovery time following high
intensity eccentric exercise, known to produce the most muscle damage and DOMS.
Interestingly, due to the increased voluntary run times, curcumin appears to be capable of
enhancing a behavioral response, which implies an important central nervous system
component (e.g., drive, motivation) that may be related to less pain and perhaps reduced
inflammatory cytokines (Davis et al. 2007). Curcumin supplementation also has an effect
on lactate, ammonia, BUN, AST, ALT, and CK (physical fatigue-associated biomarkers)
levels post exercise. Huang et al. (2015) found a significant decrease in the levels of these
metaoblites (lactate, ammonia, etc.) post exercise in the subjects given curcumin
supplementation compared with a placebo. The authors (Huang et al. 2015) also reported
increased grip strength and endurance performance among the supplemented groups.
Muscular glycogen content, an important energy source for exercise, was also
significantly increased in the groups who received the curcumin supplement as compared
to the placebo (Huang et al. 2015). From the results of these studies (Davis et al. 2007,
Huang et al. 2015), it appears that curcumin supplementation may have a wide spectrum
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of bioactivities for promoting health, improving exercise performance, preventing
fatigue, and even a potential CNS component.

2.3

Timing and Dosage of Curcumin Supplementation

Krishnakumar et al. (2012)
Curcumin has been shown to have many positive physiological actions and has
shown not to be toxic even at very high doses of 8–12 g/day, however, despite the safety,
efficacy, and well-tracked mechanisms of action, curcumin has poor systematic
bioavailability upon oral administration due to inadequate intestinal absorption, rapid
metabolism and short half-life. The low bioavailability of curcumin limits its use as a
therapeutic agent, therefore the purpose of this study was to investigate the bioavailability
of curcumin combined with the spice fenugreek as a vehicle for administration in animals
and humans. 8 human male subjects participated in this study. Each subject was tested
with the unformulated and formulated curcumin supplements. For the first test, each
subject was first given two capsules of 500 mg of unformulated curcumin and 2 ml blood
sample were withdrawn at 0, 0.5, 1, 3, 5, 8 and 24 h post-dose for analysis. After 1 week
of curcumin feeding, the subjects were given three capsules of 500 mg containing newly
formulated curcumin supplement (containing curcumin and fenugreek) and the same
protocol was repeated (the dosage of the three formulated capsules was equivalent to 600
mg of curcumin). The same was repeated again after 1 week with 250 mg formulated
supplement and the blood samples were withdrawn for analysis (the 250mg dosage was
equivalent to 100mg of unformulated curcumin). The results of this study found that in
humans, the absorption of curcumin + fenugreek supplement was 15.8 times higher in
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oral dosages of 1500 mg (equivalent to 600 mg curcumin), 12.9 times higher at 250 mg
(equivalent to 100 mg curcumin) of CGM as compared to 1000 mg of unformulated
curcumin. These results indicate that the bioavailability of curcumin is not only increased
by combining it with fenugreek, but is also dose dependent.
Summary:
The observed physiologic effects of curcumin and its use as a therapeutic agent
have been limited due to its poor systematic bioavailability upon oral administration
which is related to its inadequate intestinal absorption, rapid metabolism, and short halflife. Krishnakumar et. al. (2012) investigated the bioavailability of curcumin combined
with the herb fenugreek in animals and humans. In the human subjects who received the
formulated curcumin supplement, absorption was 15.8 times higher in oral dosages of
1500 mg (equivalent to 600 mg curcumin), and 12.9 times higher at 250 mg (equivalent
to 100 mg curcumin) as compared to 1000 mg of unformulated curcumin. The results of
this study indicate that the bioavailability of curcumin is dose dependent and increased by
combining it with fenugreek.

2.4

Development of the Physical Working Capacity at the Fatigue Threshold Model

deVries et al. (1982)
This study examined the relationship between two fatigue thresholds (critical
power [CP] and fatigue threshold [FT]), derived from unique methodologies. The CP was
determined from four, exhaustive, constant power output cycle ergometer workbouts. The
CP was defined as the slop of the relationship between the total work performed and the
time to exhaustion for the four workbouts. In addition, the anaerobic threshold (AT) was
13

determined from gas exchange and ventilatory parameters measured during an
incremental test to exhaustion. The FT was then estimated by measuring integrated
electromyographic amplitude (IEMG) from the quadriceps femoris muscle during four,
constant power output cycle ergometer workbouts. This study utilized a unipolar lead
system, with surface electrodes placed on the lateral portion of the dominant quadriceps
femoris muscle and reference electrode over the anterior superior iliac spine (ASIS). The
IEMG data was plotted over 10 second periods as a function of time during three or four
workbouts of various power outputs on the cycle ergometer. The slope coefficients from
each power output were determined and then power output was plotted against the slope
coefficients for each of three or four workbouts (fatigue slope coefficient on the x axis
and power output in W on the y). The FT was identified as the point of zero slope,
estimated from the Y intercept value and expressed in W. The FT was defined as the
highest constant power output that could be maintained during cycle ergometry without
an increase in IEMG activity. This study demonstrated a linear relationship between time
and increased IEMG activity (r = 0.88-0.99). The FT ranged from 124-284W, with a
2

mean value of 190.5 ± 14.0 W. In addition, the CP and FT as well as the AT and FT were
compared. They found that the relationship between AT and FT (r = 0.903, p<0.001) was
stronger than that between FT and CP (r= 0.860, p<0.001) and there was no significance
between AT and FT, CP was less than FT. The authors concluded that due to the
correlation found among the three variables, CP, AT and FT there may be a single
phenomenon that underlies them all, and IEMG estimation of FT may provide an
alternative to the measurement of AT.
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deVries et al. (1987)

The purpose of this study was to develop a test utilizing electromyographic
(EMG) responses from submaximal discontinuous work bouts on the bicycle ergometer
to determine the physical working capacity at the fatigue threshold (PWC FT ). The
subjects for this study included 32 males, 18-29 years old, with fitness levels ranging
from highly trained to untrained and sedentary. The same IEMG equipment and
procedures were used in this study as in the previous study conducted by deVries et al.
(1982). The onset of blood lactate accumulation (OBLA), percent heart rate range
(%HRR) at the PWCFT , heart rate- workload (HR-WL) relation, critical power (CP) and
ratings of perceived exertion (RPE) at the PWC FT were measured for each subject. These
measurements were used to examine the validity of the PWC FT model through
correlational and regression analyses. The procedures for measuring the PWC FT included
multiple discontinuous work bouts on the bicycle ergometer at increasing intensities, with
the measurement of IEMG amplitude. The subject’s heart rate returned to within 10
b·min-1 of the resting value before the next work bout was initiated. The first work bout
was performed at 420 kpm·min-1 and increased by 420 kpm·min-1 for each subsequent
work bout (3 total). The PWC FT was determined as the average of the highest power
output with no change in IEMG amplitude over time and the lowest power output that
resulted in an increase in IEMG amplitude. Seventeen of the subjects were retested on a
different day to determine the reliability of the PWC test. The authors found that PWC
FT

FT

was highly reproducible, with a test-retest correlation of r= 0.947 and a SEE of 145.6
kpm·min (9.7% of the mean PWCFT ). The results also showed the OBLA, % HRR, and
-1
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HR-WL relationship accounted for 70% of the total variance in the PWC FT . In
conclusion, the PWC FT model was shown to be valid and highly reproducible, providing
an attractive alternative to supramaximal tests for untrained or sedentary individuals.
deVries et al. (1990)
The purpose of this study was to examine alternative methodological procedures
for the determination of the physical working capacity at the fatigue threshold (PWC FT )
to improve the practical application and extend the utility of the test. This study examined
the use of a continuous test protocol rather than a discontinuous protocol. In addition, the
PWC estimates were compared for treadmill and bicycle ergometer exercise, from a
FT

bipolar electromyographic (EMG) lead system and a unipolar lead system, as well as the
potential for residual fatigue from tests repeated 24 hours apart. Twenty subjects
participated in this study, with a wide age (19-70 years) range and different fitness levels.
Each subject participated in one or more of the experiments conducted. For each
experiment EMG data and fatigue curves were recorded as previously described by
deVries et al. (1987). The initial power output was set based on the subject’s estimate of
their fitness level and abilities and was then incrementally increased by 12-25 W at each
stage for the bicycle ergometer tests and by one to two percent grade increases for the
treadmill test. The first experiment was a comparison continuous versus discontinuous
protocol on the bicycle ergometer. For the discontinuous test, the subjects rested until
their HR was within 10 b·min-1 of their resting value between each power output or grade
increase. The continuous test followed the same procedures as the discontinuous test
except for there was no rest interval between each increase in intensity. The PWC FT was
determined as the average of the highest power output with no change in IEMG
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amplitude over time and the lowest power output that resulted in an increase in IEMG
amplitude. There was no mean difference between the PWC FT estimates from the
discontinuous versus continuous test on the bicycle ergometer and they were highly
correlated (r=0.856). The PWCFT estimates from the treadmill versus bicycle ergometer
involved 6 of the 20 subjects, for both the continuous and discontinuous protocols. Since
there is no direct measurement of work or power for exercise on a treadmill, to determine
PWCFT the highest heart rates (HR) achieved during the two-minute period in which the
fatigue threshold was reached (i.e., increase in EMG amplitude) were compared from the
bicycle ergometer test and treadmill test. The EMG data were collected from the
quadriceps and gastrocnemius muscles for the treadmill test. The results showed that
there was no significant difference between the mean HR at the PWC FT between the two
different muscle groups, however, the HR at the PWC FT was 20-35 b·min-1 lower on the
bicycle ergometer compared to the treadmill. The unipolar versus bipolar lead systems
test showed that the mean voltages from the unipolar measurements were significantly
greater than for the bipolar, but they were well correlated (r=0.841). The PWCFT
estimates from unipolar and bipolar were not significantly different (t= 1.09 p>0.05).
Furthermore, the effect of 24-hour repeated tests showed that there was no residual
fatigue effect for discontinuous PWC FT tests repeated at a 24 hour interval.
Summary
The Physical Working Capacity at the Fatigue Threshold Model (PWC ) was
FT

developed by deVries et al. (1982) to examine the onset of neuromuscular fatigue. This
model utilized surface electromyography (EMG) from the quadriceps muscle. The
amplitude (AMP) of the EMG signal was plotted versus time for a series of constant
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work rate rides. The PWC was defined as the highest constant power output that could
FT

be maintained during cycle ergometry without an increase in EMG AMP. deVries et al.
expanded upon the initial study, and in 1990 an experiment to determine factors that may
affect the estimation of the PWC . Overall, it was concluded that the model could be
FT

extended to treadmill running, conducted using bipolar or unipolar leads, but most
importantly, that a continuous exercise protocol could be implemented instead of the
previously utilized, discontinuous protocol.

2.5

Utilization of PWC to Examine the Efficacy of Nutritional Supplements to
FT

Improve Performance
Camic et al (2010a)
The purpose of this study was to examine the effects of 4 weeks of arginine-based
supplementation on the physical working capacity on the fatigue threshold (PWCFT).
Arginine serves as a precursor in the production of nitric oxide (NO) and plays an
important role in endothelium-dependent vasodilation. Due to these physiological effects,
arginine supplementation may help to increase blood flow to the myocardium and
skeletal muscle. This was a double-blind, placebo-controlled, parallel design which
included 50 college aged men who were randomly placed into one of three groups: 1)
placebo, 2) 1.5 g arginine or 3) 3.0 g arginine. All of the subjects performed a presupplementation (PRE) incremental test to exhaustion on a cycle ergometer to determine
the PWCFT and performed the exact same protocol after 4 weeks of arginine
supplementation. The subjects were instructed to take one dose (4 pills) of their assigned
supplement on an empty stomach immediately after they woke up every morning with 16
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oz. of water for 28 days. The subjects were instructed not to change their dietary or
exercise habits during the supplementation period. At their post supplementation (POST)
visit subjects took one dose 60 minutes prior to the test. The incremental test to
exhaustion protocol has previously been described by deVries et. al. (1987) Surface EMG
signals were recorded from the vastus lateralis using a bipolar electrode arrangement
during the incremental tests for the determination of the PRE and POST supplementation
PWCFT values. The results of the study indicated significant increases in the PWCFT
values for the 1.5 g (22.4%) and 3.0 g (18.8%) supplement groups, but no change for the
placebo group (-1.6%). These findings were likely due to the physiologic actions of
arginine combined with grape seed extract, which help reduce the concentrations of
metabolic by-products produced during exercise, improved blood flow associated with
increased NO synthesis and decreased endothelin production. In conclusion, arginine
based supplements can be used as an ergogenic aid for untrained individuals to increase
time to fatigue and potentially improve exercise performance.
Summary
Arginine has been shown to serve as a precursor in the production of nitric oxide
(NO) and plays an important role in endothelium-dependent vasodilation (Camic et al.
2010a). Due to these physiological effects, arginine supplementation may help to increase
blood flow to the myocardium and skeletal muscle and may have an affect on the PWC .
FT

Camic et al. (2010a) conducted a study in which examined the effects 28 days of
supplementation with a placebo, 1.5g arginine, and 3.0g arginine on the PWC FT . The
results of the study (Camic et al. 2010a) indicated significant increases in the PWC FT for
the 1.5 g (22.4%) and 3.0 g (18.8%) supplement groups, but no change for the placebo
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group (-1.6%). These findings were likely due to the physiologic actions of arginine
combined with grape seed extract, which help reduce the concentrations of metabolic byproducts produced during exercise, improved blood flow associated with increased NO
synthesis, and decreased endothelin production. In conclusion, supplementation with a
compound (arginine) that improves endothelial function and blood flow can be used as an
ergogenic aid for untrained individuals to increase time to fatigue and potentially improve
exercise performance.
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CHAPTER 3. METHODS
3.1

Experimental Design and Supplementation

The present study used a randomized, double-blind, placebo- controlled, parallel design.
For this study, there were three groups, two experimental groups and one control. Due to
the low bioavailability of curcumin, it was taken in combination with galactomannan
soluble dietary fiber from fenugreek seeds in a supplement called CurQfen®, which has
been shown to significantly increase plasma concentrations of curcumin (Krishnakumar
et al. 2012). The first visit to the laboratory was to determine each subject’s PWC FT-PRE,
𝑉̇ O2 peak-PRE, and Tlim-PRE from graded exercise test to exhaustion (GXT) on an
electronically braked ergometer. Following the PRE-test, 47 subjects were randomly
assigned to either the control group (placebo: PLA, n=15), CurQfen® (CUR, n=18), or
fenugreek soluble fiber (FEN) (n=14) and were given instructions regarding the
supplementation process. The supplements were taken daily for 28 days, in the morning
before eating, with 16 oz. of water. The CurQfen® dosage was 500 mg with 100 g of
CurQfen® powder that contained 37 to 38 g of natural curcuminoids (including curcumin
(31g), demethoxy curcumin (6g) and bisdemethoxy curcumin (1.1g)) along with 60 g of
de-bitterised fenugreek dietary fiber rich in galactomannans, and a 2 to 4% moisture
content. The fenugreek only group was included to account for any extraneous effects of
fenugreek soluble fiber and contained 300mg. During the supplementation period, the
subjects were instructed not to change their dietary habits or increase their activity level.
Food logs were kept for three days prior to the PRE- and POST-test to determine the total
grams consumed for each macronutrient as well as total kilocalories. In total, 41 of the 47
subjects completed and returned the food logs for PRE- and POST-test and were included
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in the subsequent analyses of total kilocalories and grams of macronutrients consumed.
The subjects checked in every week to ensure adherence to the protocol and compliance
to the supplementation regimen. To be included in the final analyses, subjects had to
demonstrate > 80% compliance (compliance = [# of capsules consumed / # of capsules
provided] x 100). After 28 days of supplementation, the subjects returned to the
laboratory for their POST-test to determine PWCFT -POST, 𝑉̇ O2 peak-POST, and TlimPOST.

3.2

Subjects

The subjects recruited for the present investigation were college-aged, aerobically
untrained individuals. The subjects were not highly trained, specifically in bicycling, and
participated in no more than 3 days a week of regular activity (<4 hours per week). In
total, 67 subjects were recruited to participate in this study, and 47 were included in the
final analyses. Of the initial 67 subjects, three subjects withdrew from the study due to
scheduling conflicts, one withdrew due to illness, and five were excluded due to
equipment malfunctions. From the remaining 58 subjects, two were excluded due to an
inability to complete minimal stage requirements for the GXT, and nine subjects did not
have a detectable PWC FT at either the PRE- or POST-test. All of the 47 subjects included
in the final analyses were > 80% complaint (mean ± SD: 27.88 ± 0.51). All of the
subjects completed a health history questionnaire and met the following criteria: (a) no
history of medical or surgical events that could significantly affect experimental results or
increase the subjects risk of injury, these included cardiovascular disease, metabolic,
renal, hepatic, or musculoskeletal disorders; (b) were not taking any medication that
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could significantly affect experimental results; (c) not currently using any nutritional
supplements that could significantly affect experimental results; and (d) not presently
participating in another clinical trial or ingestion of another investigational product. The
study was approved by the University’s Institutional Review Board for Human Subjects,
and all subjects were given a health screening and signed a written informed consent
document before testing.

3.3

Determination of V̇O 2 peak

Each subject performed a GXT to exhaustion on a calibrated electronically-braked cycle
ergometer (Lode Corival, Groningen, The Netherlands) to determine the PWCFT , V̇O2
peak, and Tlim at PRE- and POST-test. The ergometer seat height was adjusted so that the
subject’s legs reach near full extension at the bottom of the pedal revolution. Toe clips
were used to maintain pedal contact throughout the test and all subjects were equipped
with a nose clip and a 2-way valve mouth piece to collect all expired air. Expired gas
samples were collected and analyzed using a calibrated metabolic cart (TrueMax 2400,
ParvoMedics, Sandy, UT). The gas analyzers were calibrated with room air and gases of
known concentration prior to all testing sessions. In addition, subjects wore a Polar Heart
Rate Monitor (Polar Electro Inc., Lake Success, NY), synchronized with the metabolic
cart to obtain heart rate measures throughout the ride. The test began at 50 W at a
cadence of 70 rev·min and the power output increased by 30 W every 2 min until
-1

voluntary exhaustion or the subject’s pedal rate dropped below 70 rev·min for more than
-1

10 seconds, despite strong verbal encouragement. The V̇O2 peak was defined as the
highest V̇O2 value in the last 30 seconds of the test that met two of the following three
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criteria: 1) 90% of age-predicted heart rate; 2) respiratory exchange rate > 1.1; and 3) a
plateau of oxygen uptake (less than 150 mL·minˉ¹ in V̇O 2 over the last 30 seconds of the
test).

3.4

Electromyographic Measurements
The EMG signals were measured from the vastus lateralis (VL) on the dominant

leg during the incremental test. Prior to electrode placement, the skin at each site was
shaved, carefully abraded, and cleaned with alcohol. A bipolar surface electrode (circular
24 mm, Kendall disposable EMG electrodes, Covidien LTD; Gosport Hampshire, UK)
arrangement (2.0 cm center-to-center) was placed based on the recommendations from
the SENIAM Project for EMG electrodes placement (Hermans et al. 1999). Specifically,
a reference line was drawn over the VL, one-third of the distance between the lateral
superior border of the patella and the anterior superior iliac spine. In addition, the
electrode-placement site was located 5 cm lateral to the reference line so that the
electrodes were over the VL muscle (Malek et al. 2006). A goniometer (Smith & Nephew
Rolyan, Inc., Menomonee Falls, WI) was used to orient the EMG electrodes at a 20°
angle to the reference line to approximate the pennation angle of the muscle fibers for the
VL (Abe et al. 2000). The EMG signal was amplified (gain: ×1,000) using differential
amplifiers (EMG 150 BIOPAC Systems, Inc., Santa Barbra, CA, bandwidth = 10– 500
Hz).
3.4.1

Signal Processing

The raw EMG signals were digitized at 1,000 Hz, stored in a personal computer
(MacBook Pro OSX, version 10.6.8, Apple Inc., Cuperino, CA) for subsequent analysis
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and processed with a custom program written with LabVIEW programming software
(version 7.1, National Instruments, Austin, TX). The EMG signals will be bandpassfiltered (zero phase shift, fourth-order Butterworth) at 10-500 Hz. Continuous 10 s
epochs for the EMG AMP (microvolts root mean square, μVrms) and EMG MPF (MPF
in Hz) were calculated. For the MPF analyses, each data segment was processed with a
Hamming window and a discrete Fourier transform (DFT) algorithm in accordance with
the recommendations of Hermens et al. (1999). The MPF were selected to represent the
power spectrum on the basis of the recommendations of Hermans et al. (1999) and was
calculated as described by Kwatny et al. (1970).

3.5

Determination of the Physical Working Capacity at the Fatigue Threshold

(PWCFT )
The protocol used to determine the PWC FT has previously been described in detail by
deVries et al. (1987) and was conducted simultaneously with the GXT. Briefly, the test
began at a power output of 50 W, and was increased by 30 W every 2 min until voluntary
exhaustion or the subject could no longer maintain a pedal cadence of 70 rpm. During
each 2-minute power output, 12, 10-second EMG samples were recorded from the VL
muscle. The EMG amplitude values for each of the 12, 10-second periods were plotted
across time for each power output of the test. The PWC FT was defined as the average of
the highest power output that results in a non-significant slope coefficient and the lowest
power output that results in a significant positive slope coefficient.
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3.6

Statistical Analyses

Separate, one-way ANOVAs were used to determine if there were any significant
differences among the PLA, FEN, and CUR groups for age, height, weight, PWCFT , V̇O2
peak, and Tlim , at PRE-test. The test-retest reliability (PRE- and POST-test values) for
each dependent variable was determined using the ICC 2,1 model (Weir, 2005) for the 15
subjects in the PLA group. The standard error of the measurement (SEM = SD√ 1 − 𝐼𝐶𝐶)
and minimal difference need to be considered real (MD) (MD =𝑆𝐸𝑀 𝑥 1.96 𝑥 √2 ) were
also calculated for the PLA group for each dependent variable. In addition, three separate
paired samples t-test were used to determine if there were any significant changes in the
PWCFT , 𝑉̇ O2 peak, or Tlim from PRE- to POST-test for the PLA. Three separate, one-way
ANCOVAs were used to examine differences among group for each dependent variable,
PWCFT , 𝑉̇ O2 , and Tlim . The respective PRE-test value was used as the covariate. The total
caloric (kilocalories) and macronutrient (grams of carbohydrate, fat, and protein) intake
was analyzed with separate, 3 (Group: CUR, FEN, and PLA) x 2 (Time: PRE and POST)
mixed-factorial ANOVAs. A significant main effect was followed up with one-way
ANOVAs and independent samples t-test. An alpha of p ≤ 0.05 was considered
statistically signiﬁcant for all comparisons.
CHAPTER 4. RESULTS
The results of the one- way ANOVAs comparing pre-test values indicated that there were
no significant mean group differences for the PWC FT (F= 0.705, p= 0.500), 𝑉̇ O2 (F=
1.367, p= 0.266), or Tlim (F= 0.988, p= 0.381) determined from the GXT or for age (F=
1.469 p= 0.241), height (F= 0.050 p= 0.951), or weight (F= 1.62 p= 0.209) values.
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Table 1. Demographic information and PRE test values for time to exhaustion (Tlim ), V̇O2
peak, and the physical working capacity at the fatigue threshold (PWC FT ).

Variable

Placebo (n= 15)

Fenugreek (n=14)

Curcumin (n= 18)

Age (years)

20.27

1.44

20.86

1.56

21.78

3.66

Height (cm)

174.81

6.77

175.07

7.58

175.62

8.09

Weight (kg)

73.24

12.83

79.91

12.14

71.90

13.89

Time to exhaustion
(min)

13.87

2.69

15.13

2.53

15.25

3.60

𝑉̇ O2 peak (ml·kg-1 ·min1)

39.20

8.95

37.82

6.35

42.32

8.22

PWCFT (W)

153.00

54.93

176.43

43.12

170.00

63.64

4.1

Reliability Analysis
The paired samples t-tests indicated that there were no significant mean

differences between PRE- and POST-test for the PLA group for the PWCFT (t= -0.764 p=
0.458), 𝑉̇ O2 peak (t= 0.452 p= 0.658), and Tlim (t= -0.137 p= 0.893). The ICC 2,1 values for
the PWCFT , 𝑉̇ O2 peak, and Tlim were 0.834, 0.944, and 0.953, respectively. The SEM and
MD values for the PWC FT , 𝑉̇ O 2 peak, and Tlim are presented in Table 2.
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Table 2. Results of the reliability analyses for the placebo group using PRE- and POSTtest values for the physical working capacity at the fatigue threshold (PWC FT ), 𝑉̇ O 2 peak,
and time to exhaustion (Tlim).
Subject

PREPWCFT
(W)

POSTPWCFT
(W)

1

95

155*

2

275

3

PRE𝑉̇ O2 peak
(L·min-1 )

POST𝑉̇ O2 peak
(L·min-1 )

PRE-Tlim
(min)

POST- Tlim
(min)

2.41

2.28

12.52

11.02

275

4.07

4.20

19.01

18.76

155

185

3.54

3.24

15.00

15.51

4

185

125**

3.43

2.72

14.39

13.01

5

185

155

3.42

3.51

15.50

15.52

6

155

125

2.47

2.29

12.49

11.52

7

155

155

2.15

2.08

11.01

11.40

8

125

125

2.2

2.14

11.50

11.51

9

215

245

3.61

3.72

17.51

18.40

10

65

95

2.89

3.13

14.01

15.01

11

65

95

1.58

1.40

8.51

8.01

12

125

155

3.01

3.27

15.00

16.50

13

155

155

2.56

2.61

14.00

13.32

14

155

155

2.06

2.22

11.51

12.46

15

185

185

3.31

3.46

16.00

16.51

Mean

153 ±

159 ±

2.85 ±

2.82 ±

13.87 ±

13.90 ±

± SD

54.93

49.25

0.708

0.760

2.69

3.02

ICC

0.834

0.944

0.953

SEM

21

0.171

0.61

MD

58

0.474

1.69

*Indicates that the subject had an increase in the PWC FT that exceeded the minimal
difference to be considered a real change (MD). ** Indicates that the subject had a
decrease in the PWC FT that exceeded the MD.
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4.2

Mean Group Comparisons
The one-way ANCOVA for the PWC FT values indicated there were no significant

differences among groups (F = 3.141, p= 0.053), however pairwise comparisons
indicated a significant difference between the CUR and PLA groups (p= 0.016), but no
differences between FEN and CUR (p=0.321) or FEN and PLA (p= 0.171). Therefore,
separate one-way ANCOVAs were used to examine the adjusted PWC FT means for the
PLA vs. CUR (F = 4.906, p =0.035) and the PLA vs. FEN (F = 2.969, p = 0.097). The
adjusted PWC FT mean ( SD) for the CUR (192.88

58.41W; 95% CI 175.98W-

209.77W) was significantly greater (p= 0.035) than the PLA (165.55 49.25W; 95% CI
147.02W-184.07W). The adjusted POST PWCFT means ( SD) for the PLA (166.66
49.25W; 95% CI 153.14W- 180.18W) and FEN (183.22 31.53W (95% CI 169.21W197.23W) were not significantly different (p= 0.097) (Figure 1 and 2). The one- way
ANCOVA for 𝑉̇ O2 peak (F = 0.612, p = 0.612) and Tlim (F = 0.688, p = 0.508) indicated
there were no significant differences among groups (Figure 3 and 4).
The 3 x 2 mixed factorial ANOVAs resulted in no signiﬁcant group x time
interactions, main effects for group, or main effects for time for total kilocalories, or
carbohydrates (g) and protein (g). However, there was a significant main effect for group
for fat (g) (F= 4.327, p= 0.020). A follow up one- way ANOVA (F= 4.327, p= 0.020) and
between subject t-test indicated that the fat intake (collapsed across time) was greater for
FEN compared to PLA (p= 0.015) and CUR (p= 0.014), but there was no difference
between CUR and PLA (p= 0.954). Supplement compliance was recorded with
supplementation logs and demonstrated a mean (± SD) compliance rate of 99.5% ±
0.51%.
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Figure 1. Adjusted POST-test physical working capacity at the fatigue threshold (PWCFT )
(mean SEM) values (covaried for PRE PWC FT scores) for the feugreek soluble fiber
(FEN) and placebo (PLA) groups.
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Figure 2. Adjusted POST-test physical working capacity at the fatigue threshold (PWCFT )
(mean SEM) values (covaried for PRE PWC FT scores) for the curcumin+fenugreek
soluble fiber (CUR) and placebo (PLA) groups.
*Significantly (p< 0.05) greater than placebo.

30

3.50

𝑉 ̇O 2 peak (L·min-1 )

3.00
2.50

2.00
1.50
1.00
0.50
0.00

PLA

FEN

CUR

Group

Figure 3. Adjusted POST-test peak oxygen consumption (𝑉̇ O2 peak) (mean SEM)
values (covaried for PRE 𝑉̇ O2 scores) for the curcumin+fenugreek soluble fiber (CUR),
fenugreek soluble fiber (FEN), and placebo (PLA) groups.
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Figure 4. Adjusted POST-test time to exhaustion (Tlim ) (mean SEM) values (covaried
for PRE Tlim scores) for curcumin+fenugreek soluble fiber (CUR), fenugreek soluble
fiber (FEN), and placebo (PLA) groups.
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4.3

Individual Responses

Four of the 18 subjects in the CUR group (Figure 5), one of the 14 subjects in the FEN
group (Figure 6), and one of the 15 subjects in the PLA group (Figure 7) had a value
greater than the minimal difference for the PWC FT , but none of the subjects in the PLA,
FEN, or CUR groups exceeded the MD for 𝑉̇ O2 peak or Tlim (Figures 8-13).
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0
1

2

Testing Time Point (PRE to POST)

Figure 5. Individual responses for the physical working capacity at the fatigue threshold
(PWCFT ) from PRE- to POST-test for the curcumin+fenugreek soluble fiber (CUR)
supplement group. Solid line indicates the subject had an increase greater than the
minimal difference (MD=60W). Dashed line (---) = no change, dashed and dotted line (- .
-) = decrease, and dotted line (…) = increase, not greater than the MD. Note there were 4
subjects who had increases greater than MD, two solid subject lines overlap at 155245W.
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Figure 6. Individual responses for the physical working capacity at the fatigue threshold
(PWCFT ) from PRE- to POST-test for the fenugreek soluble fiber (FEN) supplement
group. Solid line indicates the subject had an increase greater than the minimal
difference. Dashed line (---) = no change, dashed and dotted line (- . -) = decrease, and
dotted line (…) = increase, not greater than the MD.
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Figure 7. Individual responses for the physical working capacity at the fatigue threshold
(PWCFT ) from PRE- to POST-test for the placebo (PLA) supplement group. Solid line
indicates the subject had an increase greater than the minimal difference, dashed, double
dot, dashed (- . . -) line indicates the subject had a decrease greater than the minimal
difference. Dashed line (---) = no change, dashed and dotted line (- . -) = decrease, and
dotted line (…) = increase, not greater than the MD.
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Figure 8. Individual responses for 𝑉̇ O2 peak from PRE- to POST-test for the
curcumin+fenugreek soluble fiber (CUR) supplement group. Solid line indicates the
subject had an increase greater than the minimal difference, dashed, double dot, dashed
(- . . -) line indicates the subject had a decrease greater than the minimal difference.
Dashed line (---) = no change, dashed and dotted line (- . -) = decrease, and dotted line
(…) = increase.
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Figure 9. Individual responses for 𝑉̇ O2 peak from PRE- to POST-test for the fenugreek
soluble fiber (FEN) supplement group. Solid line indicates the subject had an increase
greater than the minimal difference, dashed, double dot, dashed (- . . -) line indicates the
subject had a decrease greater than the minimal difference. Dashed line (---) = no change,
dashed and dotted line (- . -) = decrease, and dotted line (…) = increase.
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Figure 10. Individual responses for 𝑉̇ O 2 peak from PRE- to POST-test for the placebo
(PLA) supplement group. Solid line indicates the subject had an increase greater than the
minimal difference, dashed, double dot, dashed (- . . -) line indicates the subject had a
decrease greater than the minimal difference. Dashed line (---) = no change, dashed and
dotted line (- . -) = decrease, and dotted line (…) = increase.
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2

Figure 11. Individual responses for time to exhaustion from PRE- to POST-test for the
curcumin+fenugreek soluble fiber (CUR) supplement group. Solid line indicates the
subject had an increase greater than the minimal difference, dashed, double dot, dashed (. . -) line indicates the subject had a decrease greater than the minimal difference. Dashed
line (---) = no change, dashed and dotted line (- . -) = decrease, and dotted line (…) =
increase.
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Figure 12. Individual responses for time to exhaustion from PRE- to POST-test for the
fenugreek soluble fiber (FEN) supplement group. Solid line indicates the subject had an
increase greater than the minimal difference, dashed, double dot, dashed (- . . -) line
indicates the subject had a decrease greater than the minimal difference. Dashed line (---)
= no change, dashed and dotted line (- . -) = decrease, and dotted line (…) = increase.
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Figure 13. Individual responses for time to exhaustion from PRE- to POST-test for the
placebo (PLA) supplement group. Solid line indicates the subject had an increase greater
than the minimal difference, dashed, double dot, dashed (- . . -) line indicates the subject
had a decrease greater than the minimal difference. Dashed line (---) = no change, dashed
and dotted line (- . -) = decrease, and dotted line (…) = increase.
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CHAPTER 5. DISCUSSION
The primary findings of the current study were that 28 days of curcumin+fenugreek
soluble fiber (CUR) and fenugreek soluble fiber (FEN) supplementation did not affect
V̇O2 peak or Tlim, but the PWCFT was greater at POST-test for the CUR, compared to the
PLA group. In addition, there was no difference in the PWC FT at POST-test between
CUR and FEN. The PWC FT increased PRE- to POST-test by 16.7% in the CUR group,
8.5% in the FEN group, and only by 3.9% in the PLA group. The increase in the PWC FT
for the CUR group in this study were consistent with the 22.4% and 18.8% increases in
the PWCFT from PRE- to POST-test previously reported (Camic et al. 2010) after 4
weeks of daily oral administration of arginine-based supplements (Camic et al. 2010).
Like arginine, one of the potential physiological actions of curcumin is its role as a
precursor to nitric oxide (NO) production, which plays an important role in endotheliumdependent vasodilation (Boonla et al. 2014). Thus, the changes in the PWC FT in the CUR
supplementation group in the present study were consistent with the changes previously
reported following 28 days of a nutritional supplement intervention without exercise
training, and may be related to increased blood flow and metabolic byproduct clearance,
triggered by increased NO bioavailability, a potent vasodilator (Camic et al 2010).
The changes observed for the PWC FT for the CUR group in this study were likely
related to the factors that underlie neuromuscular fatigue and the detection of the
threshold. The PWC FT is an electromyographic (EMG) technique that theoretically
estimates the highest power output that can be maintained for an extended period of time
without evidence of neuromuscular fatigue. Previous studies have examined the potential
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mechanisms underlying neuromuscular fatigue, which are reflected by increases in the
EMG signal and include additional motor unit recruitment and/or increases in firing rate
of the initially recruited motor units to maintain exercise at a constant power output
(Camic et al 2010, Zuniga et al). For example, it has been suggested (Camic et al 2010,
Zuniga et al 2010, Bergstrom et al 2013) that the fatigue-induced changes in EMG
amplitude may be related to the accumulation of various metabolic byproducts and/or
ions (i.e., inorganic phosphate, hydrogen ions, ammonia and potassium). Further studies
have shown that the accumulation of these metabolites and ions result in fatigue- induced
decreases in membrane excitability (Clausen 2013, Enoka and Stuart 1992), excitationcontraction coupling involving Ca ++ release and uptake from the sarcoplasmic
reticulum, myoﬁbrillar Ca ++ sensitivity for binding with troponin, actin and myosin
binding, and ATP production and breakdown (Gladden 2004, MacLaren et al 1989,
Robergs et al 2004, Westerblad et al 2002). Other studies attribute the recruitment of
additional motor units to maintain force or power output during a fatiguing task to the
decrease in intracellular pH as a result of non-mitochondrial ATP hydrolysis, which
contributes to the decline in muscle fiber conduction velocity (Lindstrom et al 1970,
Moritani et al 1982). It has been hypothesized (Camic et al 2010) that, during
incremental cycle ergometry, intracellular [H+] may rise to a critical level, decreasing
intracellular pH, and interfering with excitation–contraction coupling. These effects
may result in fatigue changes in induced motor unit activation and an increase in EMG
amplitude observed at the PWC FT .
The physiological mechanisms responsible for the ergogenic effects of curcumin
have not been fully identified, but some reported effects include increased metabolic
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byproduct clearance (Sahin et al 2016, Huang et al 2015), potentially linked to increased
NO bioavailability and the subsequent vasodilatory response (Boonla et al 2014), as well
as increased blood antioxidant capacity, and reduced oxidative stress during exercise
from decreased levels of reactive oxygen species (ROS) (Takahashi et al 2013).
Curcumin is an active ingredient of polyphenolic curcuminoids, which can be found in
the spice turmeric and has been well studied in clinical investigations over the last few
decades (Boonla et al 2014). It is possible the purported (Boonla et al 2014, Sahin et al
2016, Takahashi et al 2013) effects of curcumin supplementation to increase clearance of
metabolic byproducts through improved endothelial function, increased neuromuscular
time to fatigue and the PWC FT in this study. For example, curcumin has been shown to
decease the accumulation of metabolic byproducts such as lactate and ammonia (Sahin et
al 2016), metabolites that have previously been linked to neuromuscular fatigue as they
accumulate during repeated muscle contractions (Camic et al 2010, Zuniga et al 2010,
Bergstrom et al 2013). Thus, it is possible curcumin improves clearance of metabolic
byproducts in the muscle cells through NO mediated vasodilation may increase the time
to neuromuscular fatigue, and allow the working muscle to perform at a higher power
output without the changes in muscle activation, thus delaying the PWCFT .
In the present study, fenugreek soluble fiber was added to increase the
bioavailability of curcumin (Krishnakumar et al 2012), but it may also have physiological
effects. Fenugreek is a naturally growing plant, originating in India and Northern Africa
(Srichamroen et al 2008). The seeds and leaves have been used for hundreds of years in
Ayurvedic and Chinese medicine, however recently, preliminary animal and human trials
suggest that oral fenugreek seed powder may have possible hypoglycemic and
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antihyperlipidemic properties (Basch et al 2003). In the present study, the galactomannan
component of fenugreek was used in the CUR supplement to increase absorption from
the small intestine (Krishnakumar et al 2012). Galactomannan is a soluble fiber guar
gum, and a potential active component of fenugreek seeds (Srichamroen et al 2008).
Specifically, galactomannans from fenugreek have been shown to have effects on
glycemic and lipidemic status in rats (Srichamroen et al 2008). Specifically,
galactomannan- fed rats demonstrated significantly less adipose tissue compared to the
control, suggestive of a high metabolic rate in the tissue that were also associated with
increased release of FFA into the circulation and decreased plasma insulin levels
(Srichamroen et al 2008). The authors suggested that the reduction of plasma insulin level
in galactomannan- fed rats may increase lipolysis in adipose tissue, and consequently
increase plasma FFA levels and reduce adipocyte size (Srichamroen et al 2008). Thus, it
is possible the fenugreek component in the CUR and FEN groups increased FFA release
and decreased insulin levels. These factors may have contributed to the increased
neuromuscular time to fatigue for the CUR group by delaying the reliance on anaerobic
energy production and accumulation of metabolic byproducts from glucose metabolism.
This may also explain, in part, the non-significant difference between the CUR and FEN
group at POST-test.
In this study, it appears the purported effects of curcumin to increase NO
production and aid in metabolic byproduct clearance were effective to increase the
submaximal neuromuscular fatigue threshold (PWC FT ), but did not affect indices of
maximal performance such as Tlim and V̇O2 peak. It is possible the intensity specific
effects were related to the factors affecting V̇O2 peak and the mode of exercise to
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determine Tlim . Previous investigators (Sahin et al. 2016) have reported decreased levels
of lactate, ammonia, and muscle malondialdehyde in conjunction with increased run
times to exhaustion in rodents supplemented with curcumin compared to a placebo.
Consistent with the findings by Sahin et al. (2016), Huang et al. (2015) reported that
curcumin supplementation dose-dependently increased grip strength and endurance
performance and increased muscular glycogen content and reduced levels of physical
fatigue-associated biomarkers serum lactate, ammonia, and blood urea nitrogen compared
to the vehicle treatment (Huang et al 2015). Each of these previous endurance tests in
animal models used submaximal protocols to examine changes in Tlim (Sahin et al 2016,
Huang et al 2015). In the present study, however, a maximal GXT on a bicycle ergometer
was utilized, which may not have been sensitive to the physiological changes induced by
curcumin, due to the observed non-significant increases in time PRE to POST.
Specifically, although improved metabolic byproduct clearance may have delayed
neuromuscular fatigue and the PWC FT , an increase in Tlim for the GXT would likely be
dependent factors that increased the cellular and blood buffering capacities as well as
improved cellular respiration at maximal intensities. Thus, the results of the present study
indicated curcumin and fenugreek soluble fiber were effective to delay neuromuscular
fatigue but did not increase Tlim during a GXT. Future studies should explore the effects
of curcumin on the sustainability of submaximal exercise performed at or below the
PWCFT to determine if the factors that improved the threshold might also increase Tlim.
Similar to Tlim, there were no effects of supplementation on V̇O2 peak in the
present study. Maximal oxygen uptake (V̇O2 peak) is primarily limited by the ability of
the cardiorespiratory system to deliver oxygen to the exercising muscles (Basset et al
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2000), but is also dependent on peripheral factors related to skeletal muscle O 2 extraction
such as capillary and mitochondrial density (Basset et al 2000), which play a critical role
in improving submaximal endurance performance. Of the many factors which may
increase michondrial biogenesis, effects of endurance training have been well studied and
shown to cause an increase in mitochondrial enzyme activities, which improves
performance by enhancing fat oxidation and decreasing lactic acid accumulation at a
given V̇O2 (Zamora et al 1995). A study by Zamora et al (1995) found that following 10
weeks of endurance training in men there was a significant increase in the number of
mitochondria per area and in the relative surface occupied by the total mitochondria
profile area. In the present study, it appears 28 days of curcumin supplementation was not
effective to alter physiological mechanisms which would lead to increases in V̇O2 peak,
however previous research has demonstrated cellular effects of curcumin
supplementation in mice that were amplified with exercise (Hamidie et al 2015).
Specifically, the combination of curcumin supplementation and endurance training has
the potential to accelerate mitochondrial biogenesis in skeletal muscle by increasing
cAMP levels (Hamidie et al 2015). In the present study, subjects were only supplemented
with CUR for 28 days, during which time they were instructed not to change dietary or
exercise habits. Without an increase in endurance training during supplementation time, it
is possible that CUR supplementation alone did not have potent enough effects to
increase cardiac output, which, theoretically, would result in an increase of V̇O2 peak.
Additionally, according to Basset et al (2000), peripheral cellular changes have been
shown to improve submaximal performance. Therefore, any potential increases in
capillary and mitochondrial density as a result from curcumin supplementation may have
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had an effect on the PWC FT , a submaximal work rate, but not V̇O2 peak, which represents
maximal exercise. Future studies should aim to investigate whether a longer
supplementation period, or higher dosages of curcumin may lead to increases in V̇O2
peak. Furthermore, curcumin supplementation with endurance training should be
investigated, to determine if the combination of the two interventions may lead to an
increase in V̇O 2 peak.
In the present study, a reliability analysis was used observe individual responses
and establish the MD, to determine the magnitude of change in PRE- to POST-test values
necessary to be considered real (Weir 2005). The MD speaks to the sensitivity of the test
in distinguishing a “real” change from variation or error in measurement (Weir 2005).
The MD for the change to be real for the PWCFT was 60 W in this study, which reflected
a delay in neuromuscular fatigue by two stages from PRE to POST-test. In the PLA
group, one of the 15 subjects had a change greater than the MD, and one subject had a
change that was less than the MD (~7% of the subjects). In the FEN group, one of the 14
subjects exceeded the MD (7% of the subjects), and four out of the 18 exceeded the MD
(22% of the subjects) in the CUR group. Thus, in general the individual subject responses
in the CUR group were not necessarily reflective of the mean response for the CUR
group. Therefore, the mean difference at POST-test for the CUR was likely driven by a
few high responders (exceeded the MD) and more moderate changes for the remaining
subjects (Figures 5-13). Extended to a larger population, 4-weeks of supplementation
with curcumin may only be effective for ~20% of individuals. It is possible that the
subjects who showed improvement in this study had more potential for change, which
predisposed them to be more sensitive to actions of curcumin supplementation. Factors
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that may impact an individual’s ability to respond to supplementation include prior
training status, health history, and potential genetic factors (Roberts et al 2018). Of these
genetic factors, Bamman et al. (2007) reported that diﬀerent skeletal muscle biomarkers
exist between high responders, who showed a marked increase in muscle ﬁber crosssectional area (fCSA), relative to low responders following 16 weeks of resistance
training. A proposed mechanism for this difference in high versus low responders is the
difference in levels of skeletal muscle insulin- like growth factor-1 (IGF-1) mRNA
variants as well as an mRNA indicative of satellite cell diﬀerentiation (myogenin). These
markers were expressed higher in the high responders relative to low responders
following training (Bamman et al 2007). To date, there is limited evidence whether there
are high responders versus low responders to nutritional supplements, and the underlying
mechanisms. Future studies should aim to investigate factors affecting a subject’s
response to nutritional supplementation. Although the subjects in this study reported
training frequencies and volume consistent with moderately trained, college aged
individuals, there was a wide range of cardiorespiratory fitness levels (very poor to
superior) based on V̇O2 peak values measured from the GXT (ACSM’s Guidelines for
Exercise Testing and Prescription). In addition, subjects were eliminated from
participation if they had a history of cardiovascular or respiratory illnesses, however, no
additional measures of health status were taken beyond resting heart rate and blood
pressure. Previous investigators have observed the effects of curcumin on arterial
stiffness in mice due to aging and concluded that curcumin supplementation improves
large elastic arterial stiffening as a result of aging, NO-mediated vascular endothelial
dysfunction, decreases oxidative stress and increases collagen and advanced glycation
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end products (AGEs) in mice (Fleenor et al 2013). It is possible that the subjects who
demonstrated significant improvements after supplementation were more sensitive to
change due to factors like arterial stiffness. Future studies should examine cardiovascular
health measures and prior training status to determine if these factors are related to the
potential for an individual to respond to curcumin supplementation.
Potential limitations of this study may be the result of the inability of to
consistently monitor subject’s actives and habits over the duration of the study. To ensure
compliance, subjects were given only 7 days of the supplement at a time, along with a
dosing log and were required to check in with investigators weekly to report if they had
missed any doses before receiving their next supply. Subjects were only included in the
study if they were 80% compliant with their supplementation (compliancy = (# of doses
consumed / total # of doses provided) x 100), however, there was no measure included to
determine levels of curcumin in the circulation. Furthermore, to rule out the potential
effects of exercise or nutrition on the results, the subjects kept an exercise log over the 28
days as well as a food log for the three days leading up to the PRE-and POST tests and
were instructed not to change dietary or exercise habits. Lastly, other factors that may
affect performance, such as sleep, and study habits were not measured and quantified,
which could have an effect if changed or disrupted over the course of the study.
In conclusion, CurQfen® supplementation increased the PWC FT compared to a
placebo, but not compared to fenugreek alone. However, there were no effects of
CurQfen® on V̇O2 peak or Tlim . The mechanisms responsible for delaying time to
neuromuscular fatigue may include increased NO production, and increased blood flow
to remove metabolic byproducts. Considering individual responses, CurQfen®
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supplementation resulted in a real change in the PWC FT for a small portion of the subjects
(~20%). These findings suggested that CurQfen® supplementation without exercise
training may help to improve time to neuromuscular fatigue in certain individuals, but the
group mean analyses were not necessarily reflective of the responses for a majority of the
subjects.
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